Scholarlink

<p>Diabetic osteoporosis (DOP) is a long-term musculoskeletal complication of type 2 diabetes mellitus (T2DM) in the population. One well-known traditional Chinese medicine(TCM) medication that works effectively for DOP is Jingui Shenqi Pill (JGSQP). However, more research is needed to understand the underlying mechanisms. In this study, both the potential active targets and therapeutic mechanisms of JGSQP on DOP are explored by integrated analysis of metabolomics and network pharmacology. The metabolic pathways closely linked to the function of JGSQP, and differential metabolites were validated using plasma metabolomics. Subsequently, network pharmacology was utilized to reveal additional essential targets against DOP caused by JGSQP. JGSQP can significantly reduce bone loss, injury to trabecular bone tissue, and aberrant glucose metabolism in DOP mice. Furthermore, JGSQP also successfully restored the MC3T3-E1 cells’ impoverished proliferation brought on by excessive hyperglycemia. Using network pharmacology analysis in conjunction with liquid chromatography coupled with liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (LC-Q-TOF/MS), 143 JGSQP components—or 277 targets—were found. 3168 targets were connected to DOP. Among them, 152 targets overlapped with known DOP treatment-related targets as potential targets for JGSQP treatment of DOP. TP53, TNF, IL-1β, and NFKBIA2 were identified by protein-protein interaction (PPI) analysis as possible targets. Moreover, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis revealed that the AGE-RAGE signaling pathway and NF-κB signaling pathway in diabetic complications were the key pathways through which JGSQP exerts its therapeutic effects on DOP. The compound reaction-enzyme-gene network diagram was created by enriching the major metabolic pathways of tryptophan metabolism and amino sugar metabolism. Finally, further experimental data verified that JGSQP treatment could significantly reduce the expression levels of inflammatory factors IL-1β and IL-6, and AGE, NFKB in MC3T3-E1 cells. JGSQP can reduce DOP by regulating the pathway to reduce inflammation and improve metabolism. The study offers a theoretical foundation for the investigation of TCM in the treatment of DOP from various perspectives and uncovers the intricate mechanism of JGSQP in the treatment of DOP.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Uncovering the mechanisms of Jingui Shenqi pill alleviates type 2 diabetic osteoporosis using a combined network pharmacology and metabolomics approach

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月8日

查看全文
  • YanLing Zhang,
  • YaLan Huang,
  • Xiu Liu,
  • Fan Xiao,
  • Jianhua Huang,
  • Yongjun Wu,
  • Rong Yu

摘要

Diabetic osteoporosis (DOP) is a long-term musculoskeletal complication of type 2 diabetes mellitus (T2DM) in the population. One well-known traditional Chinese medicine(TCM) medication that works effectively for DOP is Jingui Shenqi Pill (JGSQP). However, more research is needed to understand the underlying mechanisms. In this study, both the potential active targets and therapeutic mechanisms of JGSQP on DOP are explored by integrated analysis of metabolomics and network pharmacology. The metabolic pathways closely linked to the function of JGSQP, and differential metabolites were validated using plasma metabolomics. Subsequently, network pharmacology was utilized to reveal additional essential targets against DOP caused by JGSQP. JGSQP can significantly reduce bone loss, injury to trabecular bone tissue, and aberrant glucose metabolism in DOP mice. Furthermore, JGSQP also successfully restored the MC3T3-E1 cells’ impoverished proliferation brought on by excessive hyperglycemia. Using network pharmacology analysis in conjunction with liquid chromatography coupled with liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (LC-Q-TOF/MS), 143 JGSQP components—or 277 targets—were found. 3168 targets were connected to DOP. Among them, 152 targets overlapped with known DOP treatment-related targets as potential targets for JGSQP treatment of DOP. TP53, TNF, IL-1β, and NFKBIA2 were identified by protein-protein interaction (PPI) analysis as possible targets. Moreover, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis revealed that the AGE-RAGE signaling pathway and NF-κB signaling pathway in diabetic complications were the key pathways through which JGSQP exerts its therapeutic effects on DOP. The compound reaction-enzyme-gene network diagram was created by enriching the major metabolic pathways of tryptophan metabolism and amino sugar metabolism. Finally, further experimental data verified that JGSQP treatment could significantly reduce the expression levels of inflammatory factors IL-1β and IL-6, and AGE, NFKB in MC3T3-E1 cells. JGSQP can reduce DOP by regulating the pathway to reduce inflammation and improve metabolism. The study offers a theoretical foundation for the investigation of TCM in the treatment of DOP from various perspectives and uncovers the intricate mechanism of JGSQP in the treatment of DOP.